Skip to main content

Table 1 Maternal and reproductive parameters at the time of cesarean section in the HFD-dNONcNZO mice and those receiving tacrolimus or metformin

From: Tacrolimus in the prevention of adverse pregnancy outcomes and diabetes-associated embryopathies in obese and diabetic mice

 

Maternal BWt (g)

Mean BG (mmol/L)

No. of litters

Litters with viable fetuses

No. total implants

No. total fetuses

Total viable fetuses

% viable fetuses

Implantation sites/litter (mean ± SD)

No. resorption/litter (mean ± SD) % (mean ± SD)

No. fetuses/litter (mean ± SD)

Viable fetuses/litter at necropsy (mean ± SD) (%) (mean ± SD)

Fetal viability 1 h post necropsy (%) viable at parturition

Male:female ratio

Fetal wt. (m)

Placental wt. (g)

HFD-dNONCNZO

57.5 ± 8.1

14.67 ± 1.96

4

3

21

10

3

30

5.25 ± 1.17

2.75 ± 0.50 (55 ± 10.6)

2.5 ± 1.29

0.75 ± 0.50 (33.0 ± 19.1)

0

50:50

1.30 ± 0.57

0.213 ± 0.14

TACRO (0.05 mg/kg)

38.7 ± 0.81a

7.60 ± 0.71a

3

3

26

23

22

96

8.67 ± 0.58a

1.0 ± 1.73 (16.5 ± 19.1)

7.67 ± 1.53a

7.33 ± 1.15 (96.3 ± 7.78)

91.0 ± 10.1b

40:60

1.01 ± 0.325

0.181 ± 0.050a

TACRO (0.1 mg/kg)

45.07 ± 3.72

7.13 ± 1.59a

3

3

23

19

18

95

7.13 ± 1.53

1.33 ± 0.71 (16.7 ± 6.5)

6.33 ± 1.53a

6.0 ± 2.0 (93.3 ± 11.5)b

89.0 ± 19.1b

62:38

1.37 ± 0.209

0.204 ± 0.024

Metformin (200 mg/dL)

54.22 ± 1.63a

9.62 ± 2.63a

3

3

27

21

17

81

9.0 ± 2.05a

2.0 ± 2.65 (18.7 ± 23.5)

7.00 ± 1.00a

5.67 ± 1.15 (82.0 ± 40.1)

80.0 ± 41.5b

52:48

0.847 ± 0.33b

0.1684 ± 0.029b

  1. HFD-dNONcNZO data are presented as mean ± SD
  2. TACRO tacrolimus, BG blood glucose
  3. aSignificantly different from HFD-dNONcNZO, p < 0.05 Kruskal–Wallis
  4. bSignificantly different from HFD-dNONcNZO, p < 0.01 Kruskal–Wallis